Technology

Human SH3 domains offer unique advantages as targeting scaffolds due their small size (6 kD), extreme modularity (context-independent functionality), superior targetability, and advantageous biophysical properties (folding, solubility, stability).

These properties make drSH3 domains ideal fusion partners for IgG molecules to construct next generation therapeutic antibodies with enhanced binding affinities and capacity for multispecific target recognition.

Via engineering of the two flexible loops in the SH3 fold drSH3 domains capable of targeting any protein of interest with high affinity and specificity can be conveniently developed.

drSH3 = double-randomized SH3